ALETA-001

N/A

Report date: 2023/09/25 20:03:35

Base Information

Drug NameALETA-001
Drug Alias NameCAR-CD19 T cellsALETA-001
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD20Anti-CD19
TargetsB-lymphocyte antigen CD20B-lymphocyte antigen CD19
Therapy Area/IndicationsHematologic NeoplasmsLymphoma, Mantle-CellLymphoma, Follicular +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAleta BioTherapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesAleta BioTherapeutics Inc
Inactive CompaniesN/A
Active IndicationsHematologic NeoplasmsLymphoma, Mantle-CellLymphoma, Follicular +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A